Breath-Based Diagnostics: Measuring the Liver’s Functional Reserve in Real Time: CGH | August 2026

Introduction:

Current assessment of chronic liver disease relies largely on static biomarkers and structural measurements such as laboratory scores, elastography, imaging, and liver biopsy. However, fibrosis severity does not always parallel the liver's remaining functional capacity. Breath-based diagnostics offer a different approach by measuring real-time hepatic metabolism and metabolic reserve.

This review examines isotope-based breath tests, volatile organic compounds (VOCs), and the emerging multisubstrate Liver Isoform Breath Assessment (LIBRA) platform.

Why was this review needed?

Liver biopsy measures structure but is invasive and cannot dynamically assess hepatic function.

MELD and conventional laboratory tests provide indirect and relatively static information.

Elastography evaluates fibrosis but does not directly measure functional hepatocyte reserve.

A noninvasive test integrating liver metabolism, perfusion, mitochondrial function, and functional hepatocyte mass could improve risk stratification.

Key Takeaways:

¹³C-labeled substrates are metabolized by the liver, producing measurable ¹³CO₂ in exhaled breath.

Breath-test kinetics therefore provide a dynamic measure of hepatic enzymatic activity, mitochondrial function, perfusion, and functional hepatocyte mass.

Fibrosis alters hepatic architecture and blood flow, producing measurable changes in substrate metabolism even though breath tests do not directly measure fibrosis.

Single-substrate tests such as ¹³C-methacetin and LiMAx have demonstrated associations with fibrosis and hepatic functional capacity.

In MASLD, breath testing may detect metabolic dysfunction before advanced structural fibrosis becomes apparent.

VOCs—including acetone, pentane, trimethylamine and limonene—can provide metabolic signatures reflecting oxidative stress, lipid peroxidation, and impaired hepatic clearance.

Machine learning applied to VOC profiles may further improve identification and phenotyping of liver disease.

LIBRA represents a next-generation multisubstrate approach designed to interrogate several hepatic metabolic pathways simultaneously rather than relying on a single pathway.

Preliminary evidence suggests potential applications in fibrosis risk stratification, prediction of hepatic decompensation, and liver transplant assessment.

Breath testing should currently be considered complementary to—not a replacement for—elastography, laboratory biomarkers, imaging, or histology.

Clinical Impact:

The important conceptual advance is the shift from asking only “How fibrotic is the liver?” to also asking “How much functional metabolic reserve does this liver still have?”

Combining structural assessment such as elastography with dynamic breath-based functional testing could eventually provide a more complete phenotype of chronic liver disease and improve prediction of decompensation and surgical or transplant risk.

Bottom Line:

Breath testing introduces a new dimension to hepatology: dynamic measurement of hepatic metabolic reserve. Multisubstrate platforms such as LIBRA could ultimately complement fibrosis assessment by showing not only how structurally damaged the liver is, but how well it still functions. Large prospective validation is now needed before routine clinical adoption.